Semaglutide for Alcohol Cessation

Introduction to Semaglutide

Semaglutide undergoes primarily proteolytic degradation rather than hepatic metabolism, supporting its safe use in patients with elevated liver enzymes, although it is contraindicated in patients with Child-Pugh C cirrhosis and should be used with caution in Child-Pugh B cirrhosis, with common adverse effects including gastrointestinal symptoms, delayed gastric emptying, and potential for gallbladder disorders 1

The American College of Cardiology and other guideline societies may recommend starting semaglutide at 0.25 mg weekly for 4 weeks, gradually increasing to 0.5 mg, 1.0 mg, and 1.7 mg weekly every 4 weeks, targeting a maintenance dose of 2.4 mg weekly, with gradual dose titration helping minimize gastrointestinal adverse effects 1

The European Society of Cardiology recommends considering semaglutide for its cardiovascular protection, with reduced risk of major adverse cardiovascular events, in addition to its renal benefits including slower eGFR decline and reduced albuminuria, significant weight loss benefits in patients with obesity, and hepatic benefits including decreased fatty degeneration of the liver and reduced liver fibrosis 1, 2
Patients with type 2 diabetes may benefit from semaglutide's established effects, including significant weight loss benefits, according to the American Diabetes Association 3

When using semaglutide for patients with potential alcohol use disorder, consider screening for contraindications, initiating with low dose and gradually titrating, monitoring for common adverse effects, assessing alcohol consumption patterns, and using standardized tools like AUDIT to measure treatment response, as recommended by the National Institute on Alcohol Abuse and Alcoholism 1